Age Management Medicine Group (AMMG)

Mapping 1.6 million gut cells to find new ways treat disease via ScienceDaily: https://bit.ly/49kNiEx. "The most comprehensive cell map of the human gut to date has been created by combining spatial and single-cell data from 1.6 million cells. Mapping the cells of the gut can provide us with further insights into what happens in conditions such as bowel cancer and Inflammatory Bowel Disease (IBD). Using this atlas, researchers from the Wellcome Sanger Institute and collaborators uncovered a new role of a specific gut cell, highlighting its contributions to a cycle of inflammation in some individuals, possibly causing pain and distress. The study, published today (20 November) in Nature, details how the team harmonised over 25 single-cell datasets of the human gastrointestinal (GI) tract to create the world's largest freely-available resource of the human gut to date. This includes samples from those with health conditions as well as those without. By having a more complete picture of the human gut in health and disease, researchers can identify any key changes or differences that could be involved in the onset of conditions such as ulcerative colitis and Crohn's disease, and lead to new possible targets for drug development. This paper is one of a collection of more than 40 HCA publications in Nature Portfolio journals that represent a milestone leap in our understanding of the human body. These highly complementary studies have shed light on central aspects of human development, and health and disease biology, and have led to the development of vital analytical tools and technologies, all of which will contribute to the creation of the Human Cell Atlas." READ MORE HERE: https://bit.ly/49kNiEx #MappingGutCells #GutCells #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConference

Listening for early signs of Alzheimer's disease via ScienceDaily: https://bit.ly/3OkkwKi. "Alzheimer's disease affects more than 50 million people worldwide, often devastating both the individuals who have it and their families and loved ones. It has no known cure, and the slow, progressive nature of the disease makes early diagnosis difficult. Researchers from École de Technologie Supérieure and Dartmouth University are investigating the use of earpiece microphones to spot early signs of Alzheimer's. Miriam Boutros will present their work on Tuesday, Nov. 19 as part of the virtual 187th Meeting of the Acoustical Society of America, running Nov. 18-22, 2024. People with Alzheimer's exhibit a loss of motor control along with cognitive decline. One of the earliest signs of this decay can be spotted in involuntary eye movements known as saccades. These quick twitches of the eyes in Alzheimer's patients are often slower, less accurate, or delayed compared to those in healthy individuals. "Eye movements are fascinating since they are some of the most rapid and precise movements in the human body, thus they rely on both excellent motor skills and cognitive functioning," said researcher Arian Shamei. Detecting and analyzing saccades directly requires a patient to be monitored by eye-tracking equipment, which is not easily accessible for most people. Boutros and her colleagues are exploring an alternative method using a more ubiquitous and less intrusive technology: earpiece microphones." READ MORE HERE: https://bit.ly/3OkkwKi #AlzheimersEarlyWarningSigns #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

How tau becomes a ‘bad guy’ that contributes to Alzheimer’s disease via Baylor College of Medicine: https://bit.ly/3AQnJyh. "Many studies have shown that the accumulation of the protein tau in neurons and glial cells in the brain is a main characteristic of Alzheimer’s disease and at least 24 more neurological diseases. How normal tau transforms into a tau that accumulates in the brain and contributes to the development of neurological conditions has been of the interest of the lab of Dr. Huda Zoghbi for years. Zoghbi is a Distinguished Service Professor at Baylor College of Medicine, director of the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital and a Howard Hughes Medical Institute (HHMI) investigator. “Previous studies showed that tau is chemically modified in disease, predominantly by the addition of extra phosphate to the Tyrosine groups in the protein, and that these changes play a crucial role in regulating tau accumulation,” said first author Dr. Ji-Yoen Kim, assistant professor of molecular and human genetics in the Zoghbi lab. “In this study, published in Nature Neuroscience, we investigated how ‘good tau’ became a ‘bad guy’ that contributes to Alzheimer’s disease.” TYK2 changes tau The Zoghbi lab had earlier identified TYK2 – an enzyme that adds phosphate to Tyrosine groups – as a potential regulator of tau levels and that knocking down the TYK2 gene reduced tau levels in human cells. In the current study, the team dug deeper into how TYK2 transforms tau into a protein that aggregates and propagates to neighboring cells and accumulates in tangles inside cells, influencing the development of tau-driven neurodegeneration." READ MORE HERE: https://bit.ly/3AQnJyh #Tau #Alzheimers #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

Here's What Our Sponsors Are Saying About #AMMG! Join us in Miami, FL on April 23 - 27, 2025 for the 38th Clinical Applications for #AgeManagementMedicine Conference! SAVE THE DATE: https://bit.ly/3BWYIfz #CMEEducation #ContinuingMedicalEducation #CMEConferences #AMMGSpring2025

Discovery explains kidney damage caused by blood pressure drugs via ScienceDaily: https://bit.ly/3OHDGdv. "University of Virginia School of Medicine researchers have discovered how long-term treatment of high blood pressure with commonly prescribed drugs can destroy the kidney's ability to filter and purify blood. The finding could open the door to better ways to manage high blood pressure and other vascular diseases. The class of drugs, known as renin-angiotensin system (RAS) inhibitors, block the effects of the renin enzyme, relaxing blood vessels and allowing blood to flow more easily. They are widely used as first-line medications for hypertension (high blood pressure). But long-term use can take a terrible toll on the kidney, causing scarring and other dramatic physical changes that shift the organ's focus from blood filtration to producing renin. No longer able to clean the blood of impurities, the Frankensteined kidney becomes a ""pathological neuro-immune endocrine organ,"" as the UVA researchers describe it in a new scientific paper, that can cause serious health problems. But they say their discovery sets the stage for identifying ways to protect the kidney and better treat hypertension. "The most commonly used and believed-to-be safe blood pressure medications may be damaging the kidneys,"" said researcher R. Ariel Gomez, MD, of UVA's Child Health Research Center. ""We need to accurately understand the effects of long-term use of RAS inhibitors on the kidneys." READ MORE HERE: https://bit.ly/3OHDGdv #KidneyDamage #BloodPressureDrugs #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

Revolutionary Bioengineering Research May Transform Type 1 Diabetes Care, Pave Way for Tackling Cancer and Autoimmune Disease via ScienceDaily: https://bit.ly/417alQX. "Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no longer have to rely on donors. Organ shortages and cell type mismatches will become past problems, replaced by safe, on-demand options for anyone who needs a transplant. This revolutionary field still faces many challenges, including the nontrivial task of convincing stem cells to differentiate into desired cell types for treatment. And even if the correct cells or tissues are created and can function successfully in the body, immune rejection presents a formidable barrier to their use. To overcome this obstacle, regenerative medicine treatments in use today require systemic immunosuppression, leaving patients vulnerable to environmental hazards like viruses, bacteria and cancer cells. In a novel approach to tackle these obstacles, researchers at the Medical University of South Carolina and the University of Florida recently collaborated on a novel, highly specific strategy to treat type 1 diabetes (T1D) using a tagged beta cell transplant in tandem with localized immune protection provided by specialized immune cells also tagged with a complementary but inert targeting molecule. According to Leonardo Ferreira, Ph.D., a researcher at MUSC Hollings Cancer Center and one of the principal investigators on the study, marrying stem cell engineering and regulatory T cell (Treg) engineering allowed the first step toward a readily available, off-the-shelf solution to treating T1D." READ MORE HERE: https://bit.ly/417alQX #Type1Diabetes #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

The Access Medical Labs team had an incredible time at the Age Management Medicine Group (AMMG) Conference in Salt Lake City! Greg Dwornitski, Sr. National Account Executive, and Ralph Reserve, National Account Executive, were on hand to connect with practitioners and discuss how our diagnostic solutions—like next-day results and customizable panels—can support independent practices. Thank you to AMMG for a well-organized event, and we’re already looking forward to the next conference in Miami in April 2025! #AccessMedicalLabs #AMMGConference #HolisticMedicine #Diagnostics

Wishing you and your family a very safe, healthy and happy Thanksgiving! 🍂 🦃 🌻

Physicians & Medical Professionals! Discover AMMG's Top-Rated Online Medical Courses! SAVE 20% THRU NOVEMBER 30th - Use Promo Code: BLKFRIDAY - See All Courses HERE: https://bit.ly/39kOV6p #OnlineMedicalEducation #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

Study uncovers potential new target for treatment of chronic, debilitating skin disease via ScienceDaily: https://bit.ly/3OnBBTJ. "A team of researchers at Clemson University used an innovative multiomics approach to identify key immune mechanisms in a chronic and debilitating inflammatory skin condition. The research, which was published in the journal Proceedings of the National Academy of Sciences (PNAS), offers a promising target for future therapies. Hidradenitis suppurativa (HS) is an immune disease that affects up to 4% of the global population and causes painful, recurring skin lesions and inflammation, primarily in the folds of the skin. It commonly affects women of African American descent. Shahid Mukhtar and his team -- Bharat Mishra, Nilesh Kumar and graduate student YiFei Gou -- used single-cell sequencing techniques to pinpoint CD2 as a key immune receptor with elevated expression on T cells and innate lymphoid cells (ILCs), including natural killer cells, in HS-affected skin tissue. In collaboration with researchers at the University of Alabama at Birmingham, Mukhtar's team demonstrated through organotypic skin culture experiments from HS patients that blocking CD2 led to a significant reduction in cytokine and chemokine production, along with suppression of key pathogenic gene signatures. This finding suggests that blocking CD2 may effectively reduce the inflammatory response in HS, providing a potential new therapeutic avenue for managing symptoms and improving patient quality of life." READ MORE HERE: https://bit.ly/3OnBBTJ #TreatingChronicSkinDisease #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences